Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Daily News

Worse Complications After PVI in Women Highlight Research Gaps

L.A. McKeown

August 16, 2022

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Daily News

Routine IVUS in Peripheral Interventions Supported by Small RCT

L.A. McKeown

March 09, 2022

FDA Says Newer Paclitaxel Data Is ‘Comforting’ but Limited

News Daily News

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

L.A. McKeown

January 12, 2021

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Daily News

Longer Patency, Fewer Repeat Procedures With Paclitaxel DCBs in Dialysis Patients

L.A. McKeown

August 21, 2020

News Daily News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

L.A. McKeown

June 29, 2020

News Daily News

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

L.A. McKeown

January 15, 2020

News Daily News

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

L.A. McKeown

October 09, 2019

News Daily News

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

Caitlin E. Cox

June 18, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

Advertisement

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

Worse Complications After PVI in Women Highlight Research Gaps

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

Routine IVUS in Peripheral Interventions Supported by Small RCT

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

Longer Patency, Fewer Repeat Procedures With Paclitaxel DCBs in Dialysis Patients

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content